A randomized double-blind controlled trial to assess the efficacy and safety of curcumin versus placebo in active rheumatoid arthritis patients

Authors
Category Primary study
Registry of TrialsTCTR
Year 2018
INTERVENTION: Curcumin, Placebo CONDITION: Active rheumatoid arthritis patients ; Rheumatoid arthritis Rheumatoid arthritis PRIMARY OUTCOME: DAS‐28 score [Timeframe 8 weeks Composite end point] SECONDARY OUTCOME: ACR 20 [Timeframe 8 weeks Composite endpoint] INCLUSION CRITERIA: RA (2010 ACR/EULAR criteria) Age â?Â¥ 18 years old At least moderate disease activity (DAS 28 >3.2) VAS â?Â¥ 50 Stable dose DMARDs therapy at least 1 month prior to randomization Inaccessible or denied add on therapy
Epistemonikos ID: 7c9ab0737a47471a2874771e3cff666ef87aa442
First added on: Dec 20, 2022